Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201505 | 0.87 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL17109752 | 0.87 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL11981453 | 0.85 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSD17B10KDM4EHTT | |
| SCHEMBL3293782 | 0.83 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL14927263 | 0.79 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| Ammonia Solution, Strong SCHEMBL15795498 | 0.77 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL8539215 | 0.76 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL5361699 | 0.76 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL17049151 | 0.76 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1KMT2AHSD17B10KDM4E | |
| SCHEMBL21212781 | 0.76 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1HSD17B10KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020160010-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-2576532-B1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2935236-B1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2017-11-29 | — | — | EP | disclosed |
| EP-3173406-A1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AND THEIR USE AS FUNGICIDES | BASF SE (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9663483-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, EIF4A1 | HSP90AA1 1066/4885HSP90AB1 947/4885KMT2A 2163/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | HSP90AA1 1262/4885HSP90AB1 1167/4885KMT2A 1869/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | HSP90AA1 1262/4885HSP90AB1 1167/4885KMT2A 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.